Skip to content

Released Nov 13, 2024, after the close

10-Q filed Nov 13, 2024, 44 days after period end · 0001390478-24-000021

Q3 2024 · 10-Q
Revenue—
Net Income-$7.11MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.10N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$7,329,000N/M
Operating Cash Flowderived-$7,806,000N/M

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Revenue—$0.00$0.00$0.00
Net Income-$7.11M-$9.27M-$7.02M-$7.09M
EPS Diluted-$0.10-$0.33-$0.34-$0.45

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR